C1orf112: A Potential Drug Target and Biomarker for Chromosome 1 Open Reading Frame 112

Target Name: C1orf112

NCBI ID: G55732

C1orf112

C1orf112: A Potential Drug Target and Biomarker for Chromosome 1 Open Reading Frame 112

Chromosome 1 (1p) is one of the most studied chromosomes in the human genome due to its involvement in numerous cellular processes, including DNA replication, gene expression, and chromosomal stability. Chromosome 1 open reading frame 112 (C1orf112) is a gene located on the long arm (L) of chromosome 1 that has been implicated in various cellular processes. The C1orf112 gene has been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

C1orf112 gene

The C1orf112 gene is located on the long arm (L) of chromosome 1 at position 61.8 kb. It encodes a protein named C1orf112, which is a 21-kDa protein that is predominantly expressed in the brain and nervous system. C1orf112 is involved in various cellular processes, including the regulation of cellular adhesion, cell signaling, and neurotransmitter release.

C1orf112 as a drug target

C1orf112 has been identified as a potential drug target due to its unique structure and various cellular processes. One of the most promising aspects of C1orf112 is its role in the regulation of cellular adhesion, which is critical for the maintenance of tissue structure and function. C1orf112 has been shown to play a role in the regulation of tight junction formation, which is a critical process that helps to maintain the integrity of tissues.

C1orf112 has also been shown to be involved in the regulation of neurotransmitter release, which is critical for the function of the nervous system. C1orf112 has been shown to play a role in the regulation of dopamine release from neurosecretory cells, which is a critical neurotransmitter that plays a role in various cellular processes, including mood regulation, motivation, and reward.

C1orf112 as a biomarker

C1orf112 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. One of the most promising aspects of C1orf112 as a biomarker is its potential to be used as a diagnostic marker for cancer. C1orf112 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that C1orf112 may be a useful biomarker for the diagnosis and prognosis of cancer.

C1orf112 has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. C1orf112 has been shown to be overexpressed in the brains of individuals with Alzheimer's disease and to play a role in the regulation of neurotransmitter release in these individuals. This suggests that C1orf112 may be a useful biomarker for the diagnosis and treatment of neurodegenerative diseases.

Conclusion

C1orf112 is a gene located on the long arm (L) of chromosome 1 that has been implicated in various cellular processes. Its unique structure and involvement in cellular regulation have made it an attractive target for drug development. The potential of C1orf112 as a drug target and biomarker for various diseases makes it a promising area of research for the future. Further studies are needed to fully understand the role of C1orf112 in

Protein Name: Chromosome 1 Open Reading Frame 112

The "C1orf112 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1orf112 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets